Cargando…

A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients

BACKGROUND: Despite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently,...

Descripción completa

Detalles Bibliográficos
Autores principales: Muller Bark, Juliana, Karpe, Avinash V., Doecke, James D., Leo, Paul, Jeffree, Rosalind L., Chua, Benjamin, Day, Bryan W., Beale, David J., Punyadeera, Chamindie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242862/
https://www.ncbi.nlm.nih.gov/pubmed/37031458
http://dx.doi.org/10.1002/cam4.5857
_version_ 1785054310686523392
author Muller Bark, Juliana
Karpe, Avinash V.
Doecke, James D.
Leo, Paul
Jeffree, Rosalind L.
Chua, Benjamin
Day, Bryan W.
Beale, David J.
Punyadeera, Chamindie
author_facet Muller Bark, Juliana
Karpe, Avinash V.
Doecke, James D.
Leo, Paul
Jeffree, Rosalind L.
Chua, Benjamin
Day, Bryan W.
Beale, David J.
Punyadeera, Chamindie
author_sort Muller Bark, Juliana
collection PubMed
description BACKGROUND: Despite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently, no validated therapy response biomarkers are available for monitoring GBM progression. Metabolomics holds potential as a complementary tool to improve the interpretation of therapy responses to help in clinical interventions for GBM patients. METHODS: Saliva and blood from GBM patients were collected pre and postoperatively. Patients were stratified conforming their progression‐free survival (PFS) into favourable or unfavourable clinical outcomes (>9 months or PFS ≤ 9 months, respectively). Analysis of saliva (whole‐mouth and oral rinse) and plasma samples was conducted utilising LC‐QqQ‐MS and LC‐QTOF‐MS to determine the metabolomic and lipidomic profiles. The data were investigated using univariate and multivariate statistical analyses and graphical LASSO‐based graphic network analyses. RESULTS: Altogether, 151 metabolites and 197 lipids were detected within all saliva and plasma samples. Among the patients with unfavourable outcomes, metabolites such as cyclic‐AMP, 3‐hydroxy‐kynurenine, dihydroorotate, UDP and cis‐aconitate were elevated, compared to patients with favourable outcomes during pre‐and post‐surgery. These metabolites showed to impact the pentose phosphate and Warburg effect pathways. The lipid profile of patients who experienced unfavourable outcomes revealed a higher heterogeneity in the abundance of lipids and fewer associations between markers in contrast to the favourable outcome group. CONCLUSION: Our findings indicate that changes in salivary and plasma metabolites in GBM patients can potentially be employed as less invasive prognostic biomarkers/biomarker panel but validation with larger cohorts is required.
format Online
Article
Text
id pubmed-10242862
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102428622023-06-07 A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients Muller Bark, Juliana Karpe, Avinash V. Doecke, James D. Leo, Paul Jeffree, Rosalind L. Chua, Benjamin Day, Bryan W. Beale, David J. Punyadeera, Chamindie Cancer Med RESEARCH ARTICLES BACKGROUND: Despite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently, no validated therapy response biomarkers are available for monitoring GBM progression. Metabolomics holds potential as a complementary tool to improve the interpretation of therapy responses to help in clinical interventions for GBM patients. METHODS: Saliva and blood from GBM patients were collected pre and postoperatively. Patients were stratified conforming their progression‐free survival (PFS) into favourable or unfavourable clinical outcomes (>9 months or PFS ≤ 9 months, respectively). Analysis of saliva (whole‐mouth and oral rinse) and plasma samples was conducted utilising LC‐QqQ‐MS and LC‐QTOF‐MS to determine the metabolomic and lipidomic profiles. The data were investigated using univariate and multivariate statistical analyses and graphical LASSO‐based graphic network analyses. RESULTS: Altogether, 151 metabolites and 197 lipids were detected within all saliva and plasma samples. Among the patients with unfavourable outcomes, metabolites such as cyclic‐AMP, 3‐hydroxy‐kynurenine, dihydroorotate, UDP and cis‐aconitate were elevated, compared to patients with favourable outcomes during pre‐and post‐surgery. These metabolites showed to impact the pentose phosphate and Warburg effect pathways. The lipid profile of patients who experienced unfavourable outcomes revealed a higher heterogeneity in the abundance of lipids and fewer associations between markers in contrast to the favourable outcome group. CONCLUSION: Our findings indicate that changes in salivary and plasma metabolites in GBM patients can potentially be employed as less invasive prognostic biomarkers/biomarker panel but validation with larger cohorts is required. John Wiley and Sons Inc. 2023-04-09 /pmc/articles/PMC10242862/ /pubmed/37031458 http://dx.doi.org/10.1002/cam4.5857 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Muller Bark, Juliana
Karpe, Avinash V.
Doecke, James D.
Leo, Paul
Jeffree, Rosalind L.
Chua, Benjamin
Day, Bryan W.
Beale, David J.
Punyadeera, Chamindie
A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients
title A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients
title_full A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients
title_fullStr A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients
title_full_unstemmed A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients
title_short A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients
title_sort pilot study: metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242862/
https://www.ncbi.nlm.nih.gov/pubmed/37031458
http://dx.doi.org/10.1002/cam4.5857
work_keys_str_mv AT mullerbarkjuliana apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT karpeavinashv apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT doeckejamesd apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT leopaul apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT jeffreerosalindl apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT chuabenjamin apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT daybryanw apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT bealedavidj apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT punyadeerachamindie apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT mullerbarkjuliana pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT karpeavinashv pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT doeckejamesd pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT leopaul pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT jeffreerosalindl pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT chuabenjamin pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT daybryanw pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT bealedavidj pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients
AT punyadeerachamindie pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients